The FDA previously rejected Zycubo for Menkes disease in October last year, citing issues with the drug’s manufacturing ...
As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
Monoclonal antibodies (mAbs) aid the body against autoimmune diseases and cancer, among other things. Patients have to pick ...
Biomacromolecules are increasingly important for treating major diseases such as tumors, infections, cardiovascular diseases, metabolic disorders, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback